- |||||||||| Review, Journal: Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. (Pubmed Central) - Sep 1, 2024
Due to the potential significant impairment in quality of life caused by pouchitis, it is essential to address the gaps in knowledge for both patients and physicians in its treatment. Therefore, well-designed and adequately powered studies should assess the optimal treatment for pouchitis.
- |||||||||| Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. (Pubmed Central) - Sep 1, 2024
agent, as reported by 2 studies...Safety was comparable across therapies. Future studies should explore the literature gaps identified, including limited comparative studies with small sample sizes, variations in study designs and patient characteristics, varied definitions of CR, and limited use of patient-reported outcome measures in real-world settings.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Case 328: Brown Tumor in Hyperparathyroidism Due to Parathyroid Adenoma. (Pubmed Central) - Aug 27, 2024 inhibitor (adalimumab), which was effective for pain, the patient was lost to follow-up...Routine blood tests revealed a normal blood cell count, creatinine level of 0.64 mg/dL (56.58 ?mol/L) (normal range, 0.30-1.1 mg/dL [26.52-97.24 ?mol/L]), C-reactive protein level of 1.1 mg/dL (normal, <1 mg/dL), and vitamin D level of 21 ng/mL (52.42 nmol/L) (normal range, 30-100 ng/mL [74.88-249.60 nmol/L]). Noncontrast MRI of the thoracic and lumbar spine, MRI of the sacroiliac joints, and CT of the abdomen and pelvis were performed.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Treatment of facial and axillary lupus miliaris with adalimumab. (Pubmed Central) - Aug 26, 2024 Furthermore, the preliminary results related to the molecular mechanisms of NET formation in JIA patients provide a theoretical basis for NET-targeted therapy. No abstract available
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Journal: Clinical and Ultrasonographic Remission in Bio-na (Pubmed Central) - Aug 23, 2024 UPARAREMUS is the first study evaluating the efficacy of upadacitinib in reaching both clinical and US remission in patients with RA. At 24
- |||||||||| Review, Journal: Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors (Pubmed Central) - Aug 23, 2024
Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.
- |||||||||| Review, Journal: Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. (Pubmed Central) - Aug 17, 2024
Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups. This systematic review provides robust evidence regarding treatment options for individuals with psoriasis and MD, emphasizing the potential benefits of specific drugs in managing both conditions concurrently.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Review, Journal: Pyodermatitis-pyostomatitis vegetans: a case report and systematic review focusing on oral involvement. (Pubmed Central) - Aug 17, 2024 There is no established therapeutic protocol for PSV and management primarily consists of topical and/or systemic corticosteroids, antirheumatic drugs (sulfasalazine, mesalazine), monoclonal antibody (infliximab, adalimumab) immunosuppressives (azathioprine, methotrexate), antibiotics (dapsone), or a combination of these. The risk of recurrence of oral lesions is considerable when the medication dose is decreased or fully interrupted.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Treatment Persistence Among Advanced Therapy-Na (Pubmed Central) - Aug 14, 2024 Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy. This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-na
- |||||||||| Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. (Pubmed Central) - Aug 9, 2024 In patients with moderate to severely active RA, adalimumab-adbm and adalimumab reference product were both associated with clinically meaningful improvements in SF-36 PCS, MCS, and domain scores that were highly similar at weeks The most commonly used drugs at inclusion were Humira
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases. (Pubmed Central) - Aug 8, 2024 Despite a reduction in sensitivity, our system demonstrated a concentration-dependent response to NO, successfully secreting functional nanobodies with binding affinities comparable to the commonly used drug Adalimumab, as confirmed by enzyme-linked immunosorbent assay and in vitro assays...Additionally, we provided a mathematical framework to assess critical parameters in engineering probiotic systems, including the production and diffusion of relevant molecules, bacterial colonization rates, and particle interactions. This integrated approach expands the synthetic biology toolbox for EcN-based therapies, providing novel parts, circuits, and a model for tunable responses at inflammatory hotspots.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Adalimumab-induced leukocytoclastic vasculitis in a patient with ankylosing spondylitis: A case report. (Pubmed Central) - Aug 8, 2024 Discontinuation of adalimumab and treatment with high dose glucocorticoids and intravenous pulse of cyclophosphamide resulted in the resolution of her ischemic lesions. This case underscores the importance of considering drug-related side effects in patients with new skin lesions, particularly in the context of rheumatic diseases such as AS.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Lichenoid Drug Eruption Secondary to Adalimumab: A Case Report. (Pubmed Central) - Aug 8, 2024 The discontinuation of adalimumab must be carefully weighed against its therapeutic benefits, as the discontinuation might trigger a severe form of inflammation in the primary autoimmune disease being treated. Extreme caution, early intervention, and a multidisciplinary approach are best for the overall well-being and optimal care of the individual.
|